Drug intelligence / Profile preview

IL-23 cell therapy (Alcamena Stem Cell Therapeutics)

Development stage: Preclinical
Lead developer: Alcamena Stem Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

Alcamena Stem Cell Therapeutics is developing an unnamed cell therapy targeting Interleukin-23 (IL-23) for the treatment of plaque psoriasis. Currently in the discovery phase, this therapeutic approach likely involves engineering cells to modulate the IL-23 pathway, which is a key driver in the pathogenesis of psoriasis. By targeting IL-23, the therapy aims to reduce the inflammatory response and skin lesions associated with the disease. The asset is part of a broader pipeline of cell-based therapies being developed by the company for various inflammatory and autoimmune conditions.

Targets

IL-23 (Interleukin-23)

Beyond the preview

Go deeper on IL-23 cell therapy (Alcamena Stem Cell Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL-23 cell therapy (Alcamena Stem Cell Therapeutics).

Explore the full profile